MorphoSys AG American Depositary Shares - MOR STOCK NEWS

MorphoSys reported U.S. net product sales of Monjuvi at US$ 23.3 million for Q2 2022, showing a 25% quarter-over-quarter and 29% year-over-year growth. Total revenues reached € 59.4 million, a 55% increase compared to Q2 2021. However, the company encountered a significant net loss of € 235.0 million in Q2. R&D expenses surged to € 60.9 million as the company focuses on clinical studies. MorphoSys revised its 2022 financial guidance, projecting Monjuvi sales between US$ 90 million and 110 million.

MorphoSys AG will publish its Q2 and H1 2022 financial results on August 3, 2022, at 10:00 PM CEST. A conference call is scheduled for August 4, 2022, at 2:00 PM CEST, where the management team will discuss the results and provide an outlook for the year. Investors can access the live webcast and presentation on the company’s website. The call will include a Q&A session and a replay will be available post-event. MorphoSys is committed to advancing cancer treatments through its innovative biopharmaceuticals.

MorphoSys AG reported preliminary Q2 2022 U.S. net product sales of Monjuvi totaling US$ 23.3 million, achieving US$ 41.9 million in sales for the first half of 2022. The company updated its full-year sales guidance for Monjuvi to US$ 90 to 110 million, down from the previous range of US$ 110 to 135 million. R&D expense guidance was lowered to €275 to 300 million due to licensing agreements for felzartamab and MOR210. SG&A expenses are now expected to be €150 to 165 million.

MorphoSys AG reported preliminary Q2 2022 U.S. net product sales of Monjuvi amounting to US$ 23.3 million and US$ 41.9 million for the first half of 2022. The company has updated its 2022 financial guidance, projecting Monjuvi net sales between US$ 90 million and US$ 110 million, down from US$ 110 million to US$ 135 million. Additionally, R&D expenses are now estimated at €275 million to €300 million, and SG&A expenses at €150 million to €165 million. Full results will be published on August 3, 2022.

I-Mab (Nasdaq: IMAB) announced the advancement of two assets through new licensing agreements with MorphoSys AG (FSE: MOR). The agreements grant Human Immunology Biosciences, Inc. exclusive rights to develop and commercialize felzartamab and TJ210 outside Greater China. Felzartamab is in registrational trials for multiple myeloma in China, while TJ210 is undergoing Phase 1 trials in the U.S. These developments enhance I-Mab's position in the biopharmaceutical sector and aim to expedite the availability of innovative therapies to patients.

I-Mab (Nasdaq: IMAB) announced new licensing agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR) for felzartamab (TJ202/MOR202) and TJ210 (MOR210). HIBio will develop and commercialize these antibodies outside Greater China and South Korea. I-Mab retains exclusive rights for felzartamab in Greater China, having made significant progress toward its registration. The agreements aim to advance clinical development and commercialization, with ongoing trials for both products in different regions. These initiatives reflect I-Mab's strategy to expand its innovative drug pipeline globally.

MorphoSys and Human Immunology Biosciences (HIBio) have entered into agreements for HIBio to develop and commercialize the monoclonal antibodies felzartamab and MOR210. MorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments, plus royalties. This partnership allows MorphoSys to concentrate on advancing its oncology pipeline, including potential best-in-class treatments. HIBio holds exclusive rights for these antibodies globally, except in specified regions.

Pfizer, MorphoSys, and Incyte announced a clinical trial collaboration to explore the immunotherapeutic combination of Pfizer's TTI-622 with MorphoSys's Monjuvi and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation. Pfizer will lead a multicenter Phase 1b/2 study, which is set to take place in North America, Europe, and Asia-Pacific. The initiative addresses significant unmet medical needs in DLBCL treatment and follows promising preclinical data regarding TTI-622's potential efficacy.

MorphoSys AG presented promising data on pelabresib, a BET inhibitor, at the European Hematology Association Congress 2022. The results suggest potential disease-modifying effects in myelofibrosis patients, both first-line and those resistant to ruxolitinib. The MANIFEST trial showed that 68% of treatment-naïve patients achieved at least a 35% reduction in spleen volume (SVR35) after 24 weeks. Positive interim data reaffirmed the drug's efficacy alongside ruxolitinib, with further studies planned, including the Phase 3 MANIFEST-2 trial, expected to report topline data in H1 2024.